Bank of New York Mellon Corp Acquires 2,749 Shares of Genmab A/S (NASDAQ:GMAB)

Bank of New York Mellon Corp grew its holdings in shares of Genmab A/S (NASDAQ:GMAB) by 4.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 71,623 shares of the company’s stock after acquiring an additional 2,749 shares during the quarter. Bank of New York Mellon Corp’s holdings in Genmab A/S were worth $1,495,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Y Intercept Hong Kong Ltd boosted its position in shares of Genmab A/S by 371.0% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 73,696 shares of the company’s stock valued at $1,538,000 after acquiring an additional 58,048 shares during the last quarter. Cromwell Holdings LLC boosted its position in shares of Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after acquiring an additional 2,496 shares during the last quarter. ABC Arbitrage SA bought a new stake in shares of Genmab A/S during the 4th quarter valued at about $3,692,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Genmab A/S by 229.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company’s stock worth $1,033,000 after buying an additional 34,652 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in Genmab A/S by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock worth $186,000 after buying an additional 827 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $19.76 on Friday. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $31.02. The stock has a 50 day moving average price of $21.04 and a two-hundred day moving average price of $22.15. The company has a market capitalization of $13.08 billion, a P/E ratio of 11.36, a PEG ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, equities analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

Wall Street Analyst Weigh In

GMAB has been the subject of a number of recent research reports. Leerink Partnrs upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research report on Thursday, February 13th. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Truist Financial dropped their target price on Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. Finally, William Blair upgraded Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.